The Chemours Co.

The Chemours Co. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite a 1-year performance increase of 13.75%, it lags behind the S&P 500. The company has a market cap of USD 3,138 million and is currently loss-making.

The Chemours Co. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite a year-over-year performance increase, it remains below the S&P 500. The company has a market cap of USD 3,138 million and is currently loss-making, with notable financial metrics.

The Chemours Co. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite a rise in stock price over the past year, the company has underperformed relative to the S&P 500. It currently has a market cap of USD 3,138 million and is loss-making.

The Chemours Co. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite a year-over-year performance lagging behind the S&P 500, the company maintains a market capitalization of USD 3,138 million and a dividend yield of 1.67%, though it is currently operating at a loss.

The Chemours Co. has seen notable stock activity, achieving a significant intraday high and a strong weekly increase. Despite impressive year-to-date gains, the company faces challenges with high debt levels and declining long-term performance metrics, reflecting ongoing financial pressures and market volatility.

The Chemours Co. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite this milestone, the company's one-year performance lags behind the S&P 500. Operating with a market cap of USD 3,138 million, Chemours faces challenges, including a negative return on equity and ongoing losses.

The Chemours Co. has achieved a new 52-week high of USD 24.12, significantly up from its low of USD 9.13. Despite this milestone, the company has seen a slight decline in one-year performance. It has a market cap of USD 3,138 million and is currently loss-making.

The Chemours Co. achieved a new 52-week high of USD 22.49 on April 8, 2026, despite a challenging year marked by a 10.45% decline in performance. The company, with a market cap of USD 3,138 million, has a dividend yield of 1.67% and a debt-to-equity ratio of 13.88.

The Chemours Co. has achieved a new 52-week high of USD 21.89, significantly up from its low of USD 9.13. Despite this milestone, the company has seen a 1-year performance decline of 9.74%. It has a market cap of USD 3,138 million and operates at a loss.

The Chemours Co. has seen a notable rise in its stock price, achieving a significant increase on March 24, 2026. The company has demonstrated resilience with recent gains, contrasting with a decline in the S&P 500. However, it faces challenges, including high debt levels and a negative return on equity.

The Chemours Co. experienced a notable rise in stock performance, significantly outperforming the S&P 500 over the past week and year. However, the company faces long-term challenges, including a high debt-to-equity ratio and negative return on equity, indicating ongoing financial concerns amid recent volatility.

The Chemours Co. experienced a significant decline in its stock performance today, contrasting with the broader market's modest downturn. Despite a slight monthly gain, the company's financial metrics reveal a negative return on equity and a high price-to-earnings ratio, alongside a stable dividend yield and manageable debt levels.

The Chemours Co. has faced significant financial challenges, reporting a decline in net sales and operating profit for the quarter ending December 2025. Rising raw material costs and inefficiencies in inventory management have contributed to its struggles, prompting a need for strategic reassessment amid contrasting market performance.

The Chemours Co. experienced a notable stock price increase on October 13, 2025, reaching an intraday high. However, the company has struggled over the past year, with a significant decline in stock value and net profit, alongside a high debt-to-equity ratio and an attractive dividend yield.

Chemours Co., a specialty chemicals company, has seen its stock price decline recently, trading at $15.80. The stock's performance has varied against the S&P 500, with mixed returns over different time frames. Technical indicators present a complex outlook, reflecting both bullish and bearish trends.

The Chemours Co. has experienced recent stock fluctuations, with a 52-week range between $9.13 and $22.38. Technical indicators present a mixed outlook, showing both bullish and bearish signals. Over the past year, Chemours' stock has underperformed compared to the S&P 500, which has seen positive gains.